ARS Pharmaceuticals Inc (SPRY) is now in the Undervalued zone, suggesting that its current forward PS ratio of 6.92 is considered Undervalued compared with the five-year average of -11.43. The fair price of ARS Pharmaceuticals Inc (SPRY) is between 13.23 to 22.54 according to relative valuation method. Compared to the current price of 9.17 USD , ARS Pharmaceuticals Inc By Undervalued By 30.7%.

Relative Value

Fair Zone

13.23-22.54

Current Price：9.17

30.7%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is ARS Pharmaceuticals Inc (SPRY) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

ARS Pharmaceuticals Inc (SPRY) has a current Price-to-Book (P/B) ratio of 7.69. Compared to its 3-year average P/B ratio of 4.55, the current P/B ratio is approximately 68.98% higher. Relative to its 5-year average P/B ratio of 4.07, the current P/B ratio is about 89.15% higher. ARS Pharmaceuticals Inc (SPRY) has a Forward Free Cash Flow (FCF) yield of approximately -7.57%. Compared to its 3-year average FCF yield of -6.49%, the current FCF yield is approximately 16.64% lower. Relative to its 5-year average FCF yield of -6.33%, the current FCF yield is about 19.63% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for SPRY competitors is 20.93, providing a benchmark for relative valuation. ARS Pharmaceuticals Inc Corp (SPRY.O) exhibits a P/S ratio of 6.92, which is -66.93% above the industry average. Given its robust revenue growth of 1471.62%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of SPRY increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of SPRY in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is SPRY currently overvalued or undervalued?

ARS Pharmaceuticals Inc (SPRY) is now in the Undervalued zone, suggesting that its current forward PS ratio of 6.92 is considered Undervalued compared with the five-year average of -11.43. The fair price of ARS Pharmaceuticals Inc (SPRY) is between 13.23 to 22.54 according to relative valuation method. Compared to the current price of 9.17 USD, ARS Pharmaceuticals Inc is Undervalued By 30.70%.

What is ARS Pharmaceuticals Inc (SPRY) fair value?

SPRY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of ARS Pharmaceuticals Inc (SPRY) is between 13.23 to 22.54 according to relative valuation method.

How does SPRY's valuation metrics compare to the industry average?

The average P/S ratio for SPRY's competitors is 20.93, providing a benchmark for relative valuation. ARS Pharmaceuticals Inc Corp (SPRY) exhibits a P/S ratio of 6.92, which is -66.93% above the industry average. Given its robust revenue growth of 1471.62%, this premium appears sustainable.

What is the current P/B ratio for ARS Pharmaceuticals Inc (SPRY) as of Mar 03 2026?

As of Mar 03 2026, ARS Pharmaceuticals Inc (SPRY) has a P/B ratio of 7.69. This indicates that the market values SPRY at 7.69 times its book value.

What is the current FCF Yield for ARS Pharmaceuticals Inc (SPRY) as of Mar 03 2026?

As of Mar 03 2026, ARS Pharmaceuticals Inc (SPRY) has a FCF Yield of -7.57%. This means that for every dollar of ARS Pharmaceuticals Inc's market capitalization, the company generates -7.57 cents in free cash flow.

What is the current Forward P/E ratio for ARS Pharmaceuticals Inc (SPRY) as of Mar 03 2026?

As of Mar 03 2026, ARS Pharmaceuticals Inc (SPRY) has a Forward P/E ratio of -7.61. This means the market is willing to pay $-7.61 for every dollar of ARS Pharmaceuticals Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for ARS Pharmaceuticals Inc (SPRY) as of Mar 03 2026?

As of Mar 03 2026, ARS Pharmaceuticals Inc (SPRY) has a Forward P/S ratio of 6.92. This means the market is valuing SPRY at $6.92 for every dollar of expected revenue over the next 12 months.

SPRY Valuation